BioVie Inc. (BIVIW)
| Market Cap | 16.29M +2.4% |
| Revenue (ttm) | n/a |
| Net Income | -22.12M |
| EPS | -3.05 |
| Shares Out | 7.54M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,909 |
| Open | 0.3200 |
| Previous Close | 0.3500 |
| Day's Range | 0.3000 - 0.3400 |
| 52-Week Range | 0.1300 - 0.7900 |
| Beta | 0.67 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About BIVIW
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to mo... [Read more]
Full Company ProfileNews
BioVie Registration statement: Registration filing
BioVie filed a registration statement on August 14, 2026, providing details about a securities offering with the SEC.
BioVie Annual report: Q4 2026
BioVie has published its Q4 2026 annual report on August 13, 2026.
BioVie Transcript: Study result
The SUNRISE-PD phase II trial of bezisterim in early Parkinson's showed significant improvements in both motor and non-motor symptoms, especially in patients with higher baseline inflammation. Biomarker data suggest slowed neurodegeneration, and the drug was well-tolerated, supporting a phase III trial with an enrichment strategy.
BioVie Slides: Study result
BioVie has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
BioVie Press release: Study result
BioVie issued a press release on August 12, 2026, disclosing material business information to investors.
BioVie says Phase 2 SUNRISE-PD trial of bezisterim met primary endpoint
BioVie (BIVI) announced results from the company’s Phase 2 SUNRISE-PD trial evaluating its drug candidate bezisterim in early-stage Parkinson’s disease. The trial successfully met prespecified endpoin...
BioVie Registration statement: Registration filing
BioVie filed a registration statement on August 6, 2026, providing details about a securities offering with the SEC.
BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's Disease
Patients treated with bezisterim demonstrated statistically significant improvements compared to placebo on both motor and non-motor symptoms, as assessed by MDS-UPDRS 1 Parts I, II, and III, as well ...
BioVie Registration statement: Registration filing
BioVie filed a registration statement on July 31, 2026, providing details about a securities offering with the SEC.
BioVie files to sell Class A common stock, warrants, no amount given
ThinkEquity is acting as placement agent in connection with this offering.
BioVie Registration statement: Registration filing
BioVie filed a registration statement on July 17, 2026, providing details about a securities offering with the SEC.
BioVie files $300M mixed securities shelf
17:23 EDT BioVie (BIVI) files $300M mixed securities shelf
BioVie Registration statement: Registration filing
BioVie filed a registration statement on June 18, 2026, providing details about a securities offering with the SEC.
Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
BioVie Transcript: Investor update
Two major clinical readouts are expected soon for Parkinson's and Long COVID, with both trials showing promising safety and early efficacy signals. Bezisterim, the lead asset, targets inflammation and insulin resistance, offering a differentiated approach with significant market potential.
BioVie Slides: Corporate presentation
BioVie has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Join BioVie's Exclusive Live Investor Webinar and Q and A Session on June 2
CARSON CITY, Nev., May 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodege...
BioVie announces full enrollment of ADDRESS-LC trial of bezisterim
BioVie (BIVI) announced full enrollment of the Company’s ADDRESS-LC Phase 2 trial evaluating its drug candidate bezisterim for the treatment of neurological symptoms of Long COVID. The Phase 2 study…
BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
-Topline Data Release Targeted Late Summer 2026- CARSON CITY, Nev., May 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovat...
BioVie completes SUNRISE-PD trial in early-stage Parkinson’s disease
BioVie (BIVI) announced that the last patient evaluation visit has been completed for the company’s SUNRISE-PD Phase 2 trial evaluating its drug candidate bezisterim in early-stage Parkinson’s disease...
BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson's Disease
Last Patient Evaluation Visit Completed with Topline Data Release Targeted Q3-2026 Last Patient Evaluation Visit Completed with Topline Data Release Targeted Q3-2026
BioVie Quarterly report: Q3 2026
BioVie has published its Q3 2026 quarterly earnings report on May 11, 2026.
BioVie Transcript: KOL event
The event highlighted the central role of metabolic dysregulation and inflammation in neurodegenerative diseases, with bezisterim positioned as a novel anti-inflammatory agent targeting both motor and non-motor symptoms in Parkinson's. Key biomarkers include DNA methylation and biological age, with trial results expected by end of Q2 or early Q3.
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026
CARSON CITY, Nev., April 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurode...
BioVie Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators
The presentation highlighted imminent clinical data readouts for bezisterim in Parkinson's and long COVID, both representing multi-billion dollar U.S. market opportunities. The company is advancing a spin-off for its liver disease asset and is considered undervalued with strong insider ownership.